Clinical Ink
PrivateLast Round
Private Equity
Sep 23, 2026
Est. Valuation
$400M
Total Funding Raised
$4.3M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Clinical Ink is a life science technology company that provides an eSource platform for clinical trials, offering solutions for direct data capture, electronic clinical outcome assessments, and patient-reported outcomes.
Sector
Healthcare & Life Sciences
Verticals
Clinical Trials, Patient Engagement, Healthcare Analytics, Vertical SaaS
Business Model
B2B
Customer Profile
Subscription SaaS, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Clinical Ink Comparables
Compare Clinical Ink with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Signant Health | 89% | |
| THREAD | 88% | |
| Medrio | 87% |
Clinical Ink Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Equity | Sep 23, 2026 | ||||
| Corporate Funding | Dec 3, 2020 | ||||
| Buyout/LBO | Aug 4, 2020 | ||||
| Debt | May 14, 2018 | ||||
| Private Equity | May 14, 2018 | ||||
VC Round | Mar 19, 2015 |
Key People
Founding team and executive leadership
Clinical Ink Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| GI Partners | Private Equity, Buyout/LBO |
| MPM BioImpact | VC Round |
| Ardan Equity Partners | Private Equity |
| McKesson Ventures | Corporate Funding |
| FCA Venture Partners | VC Round, Series B |
| NovaQuest Capital Management | Buyout/LBO, Private Equity |
| F2 Ventures | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 23, 2026
Raised $400M led by Ardan Equity Partners.
- May 14, 2018
NovaQuest Capital Management led the round.
Clinical Ink Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Clinical Ink's valuation, stock price, and market status.
Is Clinical Ink a public or private company?
Clinical Ink is a private company.
What is the current stock price of Clinical Ink?
Clinical Ink is a private company, so its shares have no public market price. Caplight tracks Clinical Ink's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Clinical Ink worth (valuation)?
Clinical Ink's valuation is estimated at $400.0M based on funding round data.
Can I buy Clinical Ink stock?
Clinical Ink shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Clinical Ink's last funding round?
Clinical Ink's most recent funding round was Private Equity on September 23, 2026.
Who are the main investors in Clinical Ink?
Key investors in Clinical Ink include GI Partners, MPM BioImpact, Ardan Equity Partners, FCA Venture Partners, NovaQuest Capital Management.
Will Clinical Ink IPO soon?
No public IPO plans have been announced for Clinical Ink.
How can I track Clinical Ink secondary market activity?
Caplight tracks bids, offers, and trades in Clinical Ink's shares on secondary markets.